Form 4 for RVMD Revolution Medicines, Inc.
Accepted 2026-09-15 18:00:04 ET · period of report 2026-09-11 · accession 0001462808-26-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-09-15 18:00 | 2026-09-11 | RVMD | Kelsey Stephen Michael | See Remarks | M - OptEx | $41.71 | +92.5K | 384.4K | +32% | +$3.86M |
| DMT | 2026-09-15 18:00 | 2026-09-11 | RVMD | Kelsey Stephen Michael | See Remarks | S - Sale+OE | $202.36 | -92.5K | 291.9K | -24% | -$18.72M |
| DMT | 2026-09-15 18:00 | 2026-09-11 | RVMD | Kelsey Stephen Michael | See Remarks | M - OptEx | $41.71 | -92.5K | 88.1K | -51% | -$3.86M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-11 | M | A | 52,500 | $42.45 | 344,376 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. |
| 2 | Common | Common Stock | 2026-09-11 | M | A | 40,031 | $40.74 | 384,407 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. |
| 3 | Common | Common Stock | 2026-09-11 | S | D | 800 | $198.55 | 383,607 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. (F2) The transaction was executed in multiple trades at prices ranging from $198.35 to $198.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2026-09-11 | S | D | 11,833 | $200.11 | 371,774 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. (F3) The transaction was executed in multiple trades at prices ranging from $199.36 to $200.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 5 | Common | Common Stock | 2026-09-11 | S | D | 13,368 | $200.78 | 358,406 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. (F4) The transaction was executed in multiple trades at prices ranging from $200.36 to $201.33, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 6 | Common | Common Stock | 2026-09-11 | S | D | 21,447 | $201.75 | 336,959 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. (F5) The transaction was executed in multiple trades at prices ranging from $201.39 to $202.37, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 7 | Common | Common Stock | 2026-09-11 | S | D | 18,869 | $203.06 | 318,090 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. (F6) The transaction was executed in multiple trades at prices ranging from $202.41 to $203.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 8 | Common | Common Stock | 2026-09-11 | S | D | 17,949 | $203.87 | 300,141 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. (F7) The transaction was executed in multiple trades at prices ranging from $203.45 to $204.42, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 9 | Common | Common Stock | 2026-09-11 | S | D | 4,995 | $204.84 | 295,146 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. (F8) The transaction was executed in multiple trades at prices ranging from $204.46 to $205.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 10 | Common | Common Stock | 2026-09-11 | S | D | 3,270 | $205.81 | 291,876 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. (F9) The transaction was executed in multiple trades at prices ranging from $205.57 to $206.05, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F10) Includes 76,251 restricted stock units. |
| 11 | Derivative | Stock Option (Right to Buy) | 2026-09-11 | M | D | 52,500 | $42.45 | 0 | D | $42.45 · — to 2031-03-04 | 52,500 Common Stock | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. (F11) Fully vested. |
| 12 | Derivative | Stock Option (Right to Buy) | 2026-09-11 | M | D | 40,031 | $40.74 | 88,069 | D | $40.74 · — to 2035-03-01 | 128,100 Common Stock | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026. (F12) One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |